{
    "paper_id": "9e1d1334ad02220437912bf17a08303e65e2acd1",
    "metadata": {
        "title": "COVID-19 and biologics for psoriasis: a high-epidemic area experience -Bergamo",
        "authors": [
            {
                "first": "Andrea",
                "middle": [],
                "last": "Carugno",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Mario",
                "middle": [],
                "last": "Gambini",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Francesca",
                "middle": [],
                "last": "Raponi",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Pamela",
                "middle": [],
                "last": "Vezzoli",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Andrea",
                "middle": [],
                "last": "Gustavo",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "C",
                "middle": [],
                "last": "Locatelli",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Marco",
                "middle": [
                    "Di"
                ],
                "last": "Mercurio",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Elisa",
                "middle": [],
                "last": "Robustelli",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Paolo",
                "middle": [],
                "last": "Sena",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Key words: Psoriasis, Biologic therapy, COVID-19, Severe Acute Respiratory Syndrome -14",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Coronavirus -2 (SARS-CoV-2), Dermatology, Skin 15 with COVID-19 and it has become a serious public health emergency. 1 The first case in our 4 hospital was identified on February 21 st , 2020. 2 5",
            "cite_spans": [
                {
                    "start": 117,
                    "end": 118,
                    "text": "1",
                    "ref_id": "BIBREF0"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Information is still limited regarding the new coronavirus and its impact on chronic 6 immunosuppressive therapy patients. In a pre-coronavirus era, respiratory infection rates for 7 biologic therapy patients were comparable to placebo. 3 8",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "As suggested by the Italian Society of Dermatologists (SIDeMaST), 4 we advise patients 9 treated with biological drugs to carefully comply with hygiene rules, protective devices use, 10 to maintain social distancing and to not spontaneously suspend ongoing therapy but to inform 11 the dermatologist in case of symptoms. We report our experience with patients treated with 12 biological therapy for psoriasis in Bergamo, an area of high epidemic rates for COVID-19. 13",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Patients being treated at the psoriasis outpatient service of the Bergamo Hospital live in 15",
            "cite_spans": [],
            "ref_spans": [],
            "section": "14"
        },
        {
            "text": "Bergamo (86.2%, n=137), Milan (6.3%, n=10), Brescia (4.4%, n=7), Lecco (1.9%, n=3), Lodi 16 (1.3%, n=2) all Lombardy region areas with a high incidence rate of COVID-19 infections. 5 17 All patients were contacted by telephone or underwent a dermatological visit 40 to 45 days 18 after the beginning of the coronavirus epidemic (population characteristics are shown in Table  19 1). Twenty-five patients (15.7%) reported contacting established (positive nasal swab test) or 20 suspected cases of COVID-19. Eighteen of these 25 patients (72.0%) developed COVID-19 21 suspected symptoms (15 mild, 3 moderate, Table 1 ). 22",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 369,
                    "end": 378,
                    "text": "Table  19",
                    "ref_id": null
                },
                {
                    "start": 607,
                    "end": 614,
                    "text": "Table 1",
                    "ref_id": null
                }
            ],
            "section": "14"
        },
        {
            "text": "Six patients contacted us to report respiratory symptoms; as a precaution, given the limited 23 information available on the risk due to COVID-19, we temporarily discontinue therapy for 24 up to 30 days after the symptoms resolved. One patient reported serious symptoms that 25 required hospitalization (Pneumococcal pneumonia with negative COVID-19 nasal swab). 1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "14"
        },
        {
            "text": "Three patients without symptoms stopped therapy on their own and reported worsening of 2 psoriasis; all resumed treatment after receiving reassurances. Twenty-three patients reported 3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "14"
        },
        {
            "text": "having had symptoms consistent with COVID-19 (22 mild, 1 moderate), but did not stop 4 therapy. There were no significant demographic or comorbidity differences between patients 5 who had COVID-19 like symptoms and those who did not (Table 2 ). 6 7",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 233,
                    "end": 241,
                    "text": "(Table 2",
                    "ref_id": "TABREF2"
                }
            ],
            "section": "14"
        },
        {
            "text": "We observed a significant risk of infection in our area, especially for those who had close 8 contacts with potential COVID-19 patients. Therefore, we think it is essential to advise and 9 empower patients on activities that can help to limit the risk of infection. Fortunately, serious 10 cases of COVID-19 infection have not been reported and even patients who continued therapy 11 showed almost exclusively mild symptoms. As a precaution we decided on a case by case 12 basis whether to discontinue therapy, however we did not observe a more aggressive course Patients who had drug suspended (%, n) 5.6 (9/159) Table 1 .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 614,
                    "end": 621,
                    "text": "Table 1",
                    "ref_id": null
                }
            ],
            "section": "14"
        },
        {
            "text": "Characteristics of psoriatic patients on biological therapy. * In March 2020 almost only hospitalized patients were tested with COVID-19 nasal swab (n=0/1 positive nasal swab/hospitalized patients) ** Suspected COVID-19 symptoms: \"Mild\": flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved in \u22647 days without hospitalization. \"Moderate\": flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved in 8-16 days without hospitalization. \"Severe\": serious symptoms that required hospitalization; one patient reported serious symptoms that required hospitalization (Pneumococcal pneumonia with negative COVID-19 nasal swab). SD: standard deviation. Characteristics of patients with suspected COVID-19 symptoms. * Myocardial infarction, stroke, diabetes, obesity, dyslipidemia or non-alcoholic fatty liver disease. ** Suspected COVID-19 symptoms: \"Mild\": flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved in \u22647 days without hospitalization. \"Moderate\": flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved in 8-16 days without hospitalization. \"Severe\": serious symptoms that required hospitalization: one patient reported serious symptoms that required hospitalization (Pneumococcal pneumonia with negative COVID-19 nasal swab). SD: standard deviation. Statistical analysis was performed by t-test and chi-squared test. Significance value was set at p < 0.05.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "14"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Critical care utilization for the COVID-19 outbreak in 20",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Grasselli",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Pesenti",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Cecconi",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Italy: early experience and forecast during an emergency response",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Lombardy",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "JAMA",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.4031"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF1": {
            "text": "13 of suspected COVID-19 symptoms in patients who continued treatment. Moreover, we 14 observed the importance of creating an easy communication channel in order to provide 15 clinical and human support for patients. Further observation on a larger number of patients is 16 needed to investigate the risk of COVID-19 infection. 17 2. Buoro S, Di Marco F, Rizzi M, Fabretti F, Lorini FL, Cesa S, Fagiuoli S. Papa Giovanni 23 XXIII Bergamo Hospital at the time of the COVID-19 outbreak: letter from the warfront. Int J 24 Lab Hematol. 2020 Mar 28. doi: 10.1111/ijlh.13207. [Epub ahead of print]. 25 All patients (n=159) Mean age (years \u00b1 SD, Anti TNF-\u03b1 (adalimumab, etanercept, golimumab) (%, n) 33.3 (53/159) Anti IL-17 (secukinumab, ixekizumab, brodalumab) (%, n) 47.8 (76/159) Anti IL-(12)/23 (ustekinumab, guselkumab)",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "ASST Papa Giovanni XXIII, Bergamo Hospital 25 a severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2 2019 and has rapidly spread worldwide. A large number of people in Italy have been infected 3",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}